Heaven Sent Naturals, affiliates have been acquired by Wellgenix LLC/Red Oak Capital PE
The private shareholders of Heaven Sent Naturals, Puri-Clean and Covert Labs have sold a 51.5% stake in the companies, to Red Oak Capital, a Texas-based investment company that has made a wide range of investments and focuses on profitable companies, for US$25.54 million.
Heaven Sent Naturals, Puri-Clean and Covert Labs are three related companies in the nutritional supplement industry. Their products are sold in numerous independent and health food chain stores across the USA. The shareholders had built the company from a start-up to its present size over a 15-year period and recognized the need for additional expertise to take the company through the next growth stage.
Oaklins' team in Dallas advised the seller in this transaction, which was structured to deliver cash proceeds of 66% at closing and the remaining 33% to be paid annually over the next 5 years.
Talk to the deal team
Bryan Livingston
Oaklins Capital Alliance
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more